Clinical development failure
EB613, EB612 and oral OXM are still in development and may not demonstrate safety or efficacy.
- Scope
- Lead pipeline programs
- Materiality
- high
Entera Bio Ltd.
Entera Bio Ltd. is a clinical-stage biotechnology company developing oral tablet versions of peptide and protein replacement therapies. Its lead work centers on the N-Tab platform and first-in-class oral programs in osteoporosis and metabolic disease, including EB613, EB612, and oral GLP-1/GLP-2-related candidates.
−27 378,6 %
−27 235,7 %
−76,8 %
6.94
6.94
| % | |
|---|---|
| Oral peptide therapeutics | 0% Development of oral tablet formulations designed to replace injectable peptide and protein therapies. |
| Lead clinical programs | 0% EB613, EB612 and oral OXM programs targeting osteoporosis and metabolic disease. |
| Platform technology | 0% N-Tab™ delivery technology used to enable oral administration of biologics. |
| Collaborative research services | 100% Contract research and material transfer services performed for third parties. |
Entera does not yet sell approved products to commercial end customers; its current economic counterparties are...
- Research collaboration counterpartiesprimary
Third parties that pay for material transfer and research services while Entera performs contract R&D work.
- Future osteoporosis patients and physiciansemerging
Potential users of EB613 if approved, seeking an oral alternative to injectable PTH therapy.
- Future metabolic disease patients and physiciansemerging
Potential users of oral GLP-1/Glucagon or GLP-2 therapies if the programs reach commercialization.
- Strategic pharma partnerssecondary
Partners that may license, co-develop, or fund oral peptide programs to access the platform.
Entera’s operations are centered in Jerusalem, Israel, where all employees are based and core R&D work is performed...
- •Jerusalem, Israel is the main operating and R&D base
- •All employees are based in Israel
- •Advisors are located in the United States, UK, Europe and Asia
- •Contract manufacturing is performed through a UK-based CMO
- •Clinical and regulatory work is international, reducing single-country dependence
Entera is focused on advancing first-in-class oral versions of peptide therapies that are normally delivered by...
01
Advance EB613 toward phase 3short-term
EB613 is the most advanced program and could validate the platform in a large osteoporosis market.
02
Progress oral OXM with OPKOshort-term
The collaboration can expand the pipeline into metabolic disease while sharing development burden.
03
Extend N-Tab platform valuemedium-term
Platform validation across multiple peptides can improve partnering leverage and long-term optionality.
04
Secure non-dilutive or strategic fundingshort-term
Clinical development requires capital and the company has stated additional funding will be needed.
Entera is a pre-revenue clinical-stage company, so execution risk is concentrated in clinical outcomes, regulatory...
Financing risk
The company expects to need additional capital before commercialization and may not raise it on favorable terms.
- Scope
- Operating runway and trial funding
- Materiality
- high
Geopolitical risk in Israel
Employees and operations are based in Israel, so conflict could disrupt work, supply chains, or fundraising.
- Scope
- Jerusalem operations and personnel
- Materiality
- high
Regulatory risk
The company needs FDA and other regulatory alignment before advancing into later-stage trials and approval.
- Scope
- EB613 phase 3 planning
- Materiality
- high
Partner and collaboration risk
Development timelines and economics depend partly on third-party collaboration agreements.
- Scope
- OPKO collaboration and research services
- Materiality
- medium
Over-time revenue recognition for research services
Quarterly revenue can be small and uneven
Grant-related royalty and repayment obligations
Potential contingent liability and cash outflow
Clinical-stage expense recognition
Material effect on reported earnings and burn rate
Share-based compensation
Affects R&D and G&A expense
ENDRA Life Sciences Inc.
NDRA · Electromedical & Electrotherapeutic Apparatus
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
Olema Pharmaceuticals, Inc.
OLMA · Pharmaceutical Preparations
Olema Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for…
ORAMED PHARMACEUTICALS INC.
ORMP · Pharmaceutical Preparations
Entrada Therapeutics, Inc.
TRDA · Pharmaceutical Preparations
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines designed to reach intracellular targets that have historically been difficult to access.
Tyra Biosciences, Inc.
TYRA · Pharmaceutical Preparations
: 28/04/2026